Angel Arnaout, MD, MSc, FRCSC, FACS, Regional Director of Breast Surgical Oncology, part of the Ottawa Breast Cancer Biomarker Research Program at The Ottawa Hospital. In this audio, she speaks about the ASCO 2022 Abstract – Â Intratumoral (IT) INT230-6 can cause tumor necrosis In Vivo: Preliminary results of a phase II randomized presurgical window-of-opportunity study in early breast cancers (the INVINCIBLE study).
Synopsis:
This is a phase II, randomized, multi-center, parallel design, window of opportunity trial including up to 90 patients with early stage breast cancer. Patients in the treatment arm will receive intratumoral INT230-6 injections prior to breast surgery in a 2:1 randomization.